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Abstract: The development of new nanomaterials to promote wound healing is rising, because of their
topical administration and easy functionalization with molecules that can improve and accelerate the
process of healing. A nanocomposite of gold nanoparticles (AuNPs) functionalized with calreticulin was
synthetized and evaluated. The ability of the nanocomposite to promote proliferation and migration was
determined in vitro, and in vivo wound healing was evaluated using a mice model of diabetes established
with streptozotocin (STZ). In vitro, the nanocomposite not affect the cell viability and the expression of
proliferating cell nuclear antigen (PCNA). Moreover, the nanocomposite promotes the clonogenicity of
keratinocytes, endothelial cells, and fibroblasts, and accelerates fibroblast migration. In vivo, mice treated
with the nanocomposite presented significantly faster wound healing. The histological evaluation showed
re-epithelization and the formation of granular tissue, as well as an increase of collagen deposition.
Therefore, these results confirm the utility of AuNPs–calreticulin nanocomposites as potential treatment
for wound healing of diabetic ulcers.
Keywords: biomaterial; proliferation; migration; clonogenicity; gold nanoparticle; diabetic foot ulcer
1. Introduction
The treatment of chronic and acute wounds represents a challenge for the world public health.
According to a market research report, profits are expected to increase from 18.35 billion U.S. dollars in
2017 to 22.01 billion U.S. dollars by 2022 [1]. The incidence of chronic wounds (venous, diabetic foot,
or pressure ulcers) have reached epidemic proportions; furthermore, 44 to 70% of patients affected
with chronic ulcers remain unhealed, which justifies the finding of more efficient therapies [2].
Diabetes mellitus is one the most important metabolic disorders associated with significant
morbidity and mortality [3]. It is estimated that more than 326 million patients worldwide have type
2 diabetes mellitus, and 15–25% of these will develop diabetic foot ulcers [4], which if not treated
properly can lead to infection, gangrene, and extremity amputation [5,6].
In recent years, the use of gold nanoparticles (AuNPs) have created an expansion in the area in
biomedical research, due to their unique properties of small size, large surface area, high reactivity to
the living cells, and penetration into the cells [7].
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For this reason, the develop of nanocomposites functionalized with biomolecules like proteins,
antibodies, and peptides to promote the healing process have been an area of increased scientific
interest [8,9]. Also, it has been found that functionalization reduces the inflammatory activation of
T cells, mast cells, and macrophages with the release of cytokines [10].
Despite trials demonstrating that dressings incorporating recombinant growth factors and cells
are safe, and do not present secondary effects, not all dressings are efficient in the process of wound
healing [11].
Due to this situation, the present study evaluated a new nanocomposite based on gold nanoparticles
(AuNPs), chitosan, and calreticulin for the treatment of wounds in a diabetic model. This nanocomposite
was designed to take advantage of the bactericidal and anti-inflammatory properties of gold nanoparticles,
and the facility of surface modification that allows the anchoring or conjugation with biomolecules like
chitosan and calreticulin. Chitosan is a biocompatible polymer used in the synthesis of gold nanoparticles
as a reducing and stabilizing agent. It has been demonstrated that chitosan increases the proliferation
and migration of fibroblasts favoring the process of wound healing [12,13].
Furthermore, calreticulin (CRT), a 46 kDa calcium-binding resident protein of the endoplasmic
reticulum (ER), directs the proper folding of proteins and homeostatic control of cytosolic and ER calcium
levels [14]. Topically applied CRT increases the rate of wound re-epithelialization and granulation
tissue/neodermal formation compared to Regranex (platelet-derived growth factor (PGDF-BB)) used as
positive control [15,16]. Similar data were found in a mice model with poor healing diabetic wounds
topically treated with calreticulin [17].
Our research is the first to demonstrate the efficacy of a new gold calreticulin nanocomposite
based on chitosan for wound healing in a diabetes model.
2. Materials and Methods
2.1. Reagents and Chemicals
Calreticulin human recombinant protein was bought from Raybiotech, Inc. Norcross, GA, (United
States). Anti-proliferating cell nuclear antigen (PCNA) antibody and anti-mouse IgG2a Fluorescein
IsoTioCyanate (FITC) were bought from Santa Cruz Biotechnology, Dallas, TX, United States. Calreticulin
BioAssayTM Enzyme-Linked ImmunoSorbent Assay (ELISA) kit (Human) was used. Chitosan medium
molecular weight (degree of deacetylation 75–85%), gold (III) chloride hydrate, dimethyl sulfoxide
(DMSO), 4′,6-Diamidine-2′-phenylindole dihydrochloride (DAPI), phosphate buffer saline (PBS) and
antibiotic-antimicotic solution were purchased from Sigma Aldrich, St. Louis, MO, United States.
Thiazolyl blue tetrazolium bromide (MTT) was purchased from Affymetrix, Inc. Cleveland, OH, United
States. Fetal bovine serum (FBS), Trypsin-EDTA (1x), and Dulbecco´s Modified Eagle medium (DMEM)
were purchase from Gibco, Thermo Fisher Scientific, Waltham, MA, United States. De-ionized (DI)
water (Milli-Q®, Water Purification System, Merck Millipore) was also used. Human keratinocyte cells
(HaCaT), human umbilical vein endothelial cells (HUVEC) and mouse fibroblast cells (NIH/3T3) were
purchased from ATCC, Manassas, VA, United States.
2.2. Synthesis of Gold Nanoparticles
Gold nanoparticles (AuNPs) were synthetized with the modification of the Turkevich method [18],
using chitosan as reducing agent, as described in literature [19]. The gold salt solution was obtained
dissolving 1 g of HAuCl4 in de-ionized (DI) water to get 1 mM solution. Then, 3 mL was taken from
a gold salt solution and stirred at 130 rpm for 30 min at 100 ± 5 ◦C with 1 mL of chitosan 2% (w/v).
AuNP formation was confirmed by a color change from pale yellow to wine red. Finally, the AuNP
suspension was passed through 0.2 µm filter (CELLTREAT) to get AuNP stock.
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2.3. Functionalization of Gold Nanoparticles with Calreticulin
The calreticulin was reconstituted with 5 µL of calcium buffer (10 mmol/L Tris, 3.0 mmol/L
calcium, pH 7.0), as described in literature [20].
Next, the calreticulin (3.02 ng) was added to AuNPs solution, and the reaction was performed for
1 h at 4 ◦C at 130 rpm. Then the solution was ultra-centrifuged at 20,000 rpm for 20 min to separate the
functionalized AuNPs (AuNPs–calreticulin).
2.4. Characterization of Gold Nanoparticles and AuNPs–Calreticulin
Plasmon resonance (SPR) of AuNPs and AuNPs–calreticulin was measured by UV-Vis using
a NANODROP 2000c, Spectrophotometer (Thermo Scientific, Waltham, MA, United States). The zeta
potential (ZP) and nanoparticle size were determined by dynamic light scattering (DLS) in a Zetasizer
ZS90-Nano (Malvern Instruments, Malvern, United Kingdom). The results were reported as the mean
of the three measurements. All the analyses were made at 25 ◦C with a pH in the range of 6.5–7.5.
The morphology and distribution of AuNPs–calreticulin were characterized by a Titan-3000 transmission
electron microscope (TEM).
2.5. Obtention of Nanocomposite
Nanocomposites were obtained by the solvent evaporation method. AuNPs and AuNPs–
calreticulin solution was poured into a petri dish in an electric oven at 30 ◦C until the solvent was
completely evaporated.
2.6. Characterization of Nanocomposite Based in AuNPs–Calreticulin
The nanocomposites were characterized by X-ray diffraction (XRD) in a Dmax2100 (Rigaku,
Tokyo, Japan), and the CuKα radiation (1.5406 Å) was determined at 20 mA and 30 kV.
The study of the interaction of each component was carried by attenuated total reflection (ATR)
used in conjunction with the Fourier transform infrared spectroscopy (FTIR) technique. Spectra were
recorded by a universal ATR sampling accessory Perkin Elmer, by the accumulation of 16 scans at
4 cm−1 resolution. Nanocomposites were placed onto the diamond ATR crystal using a top-plate and
pressure arm. Data were analyzed with the software PERKIN ELMER spectrum 10 (Waltam, MA,
United States) [21].
2.7. Determination of Calreticulin Release from Nanocomposite
Calreticulin release was determined by a calreticulin Human ELISA kit. The solution of
AuNPs–calreticulin was placed in a shaker at 4 ◦C at 130 rpm to release the protein. The supernatants
were removed at 0, 12, 24, and 48 h, and the concentration of calreticulin release was determined
using the standard curve of calreticulin Human ELISA kit with a range detection of 0.5 at 10 ng/mL.
The percentage of calreticulin capture efficiency (CCE) and percentage of release of calreticulin (RC)
were calculated with the following equations:
CCE (%) = (concentration total calreticulin)− (concentration of calreticulin free)
÷(concentration total calreticulin)× 100
RC (%) = (concentration of calreticulin free)÷ (concentration total calreticulin)× 100
2.8. Viability Assay for Cells Treated with AuNPs–Calreticulin
HaCaT, HUVEC, and NIH/3T3 cells were maintained in DMEM medium, supplemented with 5%
of FBS and antibiotic–antimycotic solution at 37 ◦C, under a humidified atmosphere of 5% CO2 and
95% air in an incubator (CO2 Series Sheldon Mfg., Inc. Cornelius, OR, United States). Cells were seeded
to a 24-well plates at a density of 1 × 104 cells/well. After 24 h of incubation, the DMEM medium was
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replaced with fresh DMEM and the treatments; calreticulin (2.5, 5, 7, 10, and 15 pg), AuNPs (1.5, 3, 6,
and 15 µM), or AuNPs–calreticulin (1.5, 3, 6, and 15 µM) were added to the seeded cells.
The DMEM medium without calreticulin, AuNPs, or AuNPs–calreticulin served as a control,
and insulin (5 µg/mL) served as a positive control.
The viability was evaluated at 24 and 72 h by the MTT method. Spectrophotometric measurements
were done at 570 nm (n = 3). The percentage of cell viability (%) was calculated with the following equation.
Viability (%) = (Absorption sample÷Absorption control)× 100
2.9. Expression of Proliferating Cell Nuclear Antigen on Cells Treated with AuNPs–Calreticulin
The expression of PCNA in HaCaT, HUVEC, and NIH/3T3 cells was detected by indirect
immunofluorescent assay. The cells were seeded in six-well plates at a density of 1 × 104 cells/well,
in 1.5 mL of DMEM medium supplemented with 5% FBS and antibiotic–antimycotic solution at 37 ◦C,
under a humidified atmosphere of 5% CO2 and 95% air.
After 24 h of incubation, the DMEM medium was replaced with fresh DMEM and the
treatments—calreticulin (2.5, 5, 7, 10 and 15 pg), AuNPs (1.5, 3, 6, and 15 µM) or AuNPs-calreticulin
(1.5, 3, 6, and 15 µM)—were added to the seeded cells. After incubation for three days, the cells
were permeabilized with Triton 0.1% and 1% sodium citrate in PBS for 2 min and washed three times
with PBS. Then, the nonspecific binding sites were blocked with 20% FBS in PBS for 30 min and
incubated for 18 h with anti-PCNA antibody and diluted 1:50 in PBS. The presence antibodies were
detected with anti-mouse IgG2a FITC, and cells were counterstained with DAPI for 30 min. Finally,
cells were washed with methanol and methanol-PBS, and were photographed at 40× in a confocal
microscope (Olympus X70). The images were analyzed using Image-Pro Plus software, version 7.0.
(Media Cybernetics, Rockville, MD, United States), and the pixels were correlated with the intensity of
the signal.
2.10. Colony Formation Assay in Cells Treated with AuNPs-Calreticulin
HaCaT, HUVEC, and NIH/3T3 cells were seeded into six-well plates at a density of 1× 103 cell/well
in 1.5 mL of DMEM medium supplemented with 5% FBS and antibiotic–antimycotic solution at 37 ◦C
under a humidified atmosphere of 5% CO2 and 95% air. After 24 h of incubation, the DMEM medium
was replaced with fresh DMEM and the treatments—calreticulin (2.5, 5, 7, 10 and 15 pg), AuNPs (1.5, 3, 6,
and 15 µM), or AuNPs–calreticulin (1.5, 3, 6, and 15 µM)—were added to seeded cells. After seven days of
incubation with the treatments, the colonies consisted of >50 cells were fixed with 4% paraformaldehyde at
4 ◦C for 5 min, and then stained for 15 min with a solution of 0.5% crystal violet and 25% methanol (v/v),
as described in literature [22,23]. Finally, the colonies were counted under an inverted microscope (Motic
AE31 microscopio, Kowloon, Hong Kong).
2.11. Wound Healing Assay in Fibroblast Treated with AuNPs–Calreticulin
A wound-healing assay was used to determine the migration of NIH/3T3 cells treated with
calreticulin, AuNPs, or AuNPs–calreticulin. Cells were grown in six-well plates with 1.5 mL of DMEM
medium supplemented with 5% FBS and antibiotic–antimycotic solution at 37 ◦C under a humidified
atmosphere of 5% CO2 and 95% air. When the cells presented a confluence of 80%, the scratches
were performed using a 200 µL pipette tip. Afterwards, the cells were washed twice with PBS to
remove all detached cells. Next, fresh DMEM medium and the calreticulin (2.5, 5, 7, 10 and 15 pg),
AuNPs (1.5, 3, 6, and 15 µM), or AuNPs–calreticulin (1.5, 3, 6, and 15 µM) treatments were added to
the seeded cells. Wound healing was recorded by photography at 3, 6, 12, and 24 h with an inverted
microscope (Motic AE31 microscopio, Kowloon, Hong Kong). The distance was measured using
ImageJ software version 1.44. The rate of cell migration was expressed as a wound healing percent
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that represents the distance of cells moving into the scratched area for each time point, as described in
literature [24] by the following formula.
Wound closure (%) = A0 −At ÷At × 100
2.12. Induction of Diabetes with Streptozotocin (STZ)
Twenty-four BALB/C male mice aged six weeks old and weighing between 22–26 g was provided
by the bioterium of the Facultad de Ciencias Biológicas, Universidad Autónoma de Nuevo León.
All experimental protocols were approved by the ethics research and animal wellness committee
(N◦ CEIBA-2018-013) of the Facultad de Ciencias Biológicas, Universidad Autonóma de Nuevo León,
and were made according to NOM-062-ZOO-1999 (Mexican legislation) for the production, care,
and use of animals for experimental purposes. The mice were divided into two groups: healthy
(12 mice) and diabetic (12 mice). The induction of diabetes was performed with intraperitoneal
injections of STZ at a dose of 65 mg/kg body weight dissolved in citrate buffer (pH 4.5) for three
consecutive days, and the healthy group was injected intraperitoneally with citrate buffer. Blood was
drawn from the tail vein, and the glucose level was determined using a glucometer (Accu-check
Performa, Roche, Pleasanton, CA, United States). The blood glucose and body weight measurements
were performed for one month and two weeks after the last injection. Mice with blood glucose levels
>160 mg/dL were considered diabetic.
2.13. Glucose Tolerance Test in Healthy and Diabetic Mice
A glucose tolerance test was performed to detect blood levels of glucose under fasting and high
sugar consumption conditions. All mice received dextrose orally at a dose of 2 mg/Kg body weight,
and the glucose levels were determined using a glucometer (Accu-check Performa, Roche, Pleasanton,
CA, United States). The glucose measurements were performed for 2 h every 30 min.
2.14. Animal Model of Wound Healing
The model of wound healing was made 1 month after the administration of SZT and citrate buffer.
The mice were anaesthetized with an intramuscular injection of ketamine hydrochloride (80 mg/kg) and
xylazine (5 mg/kg). The operation sites were shaved and disinfected, then a 0.5× 0.5 cm rectangular-shaped
incision was made on the back of the mice, including panniculus carnosus. The clinical inspection of
animals and documentation by photography were performed for 15 days. The wound areas were measured,
and the percentage of wound closure was calculated by the following formula:
Wound closure (%) = A0 −At ÷At × 100
where A0 is the wound area at the day zero and At is the wound area at the day of evaluation.
2.15. Topical Application of Nanocomposite
The groups of healthy and diabetic mice were divided into four groups according to the treatment:
PBS, insulin, AuNP nanocomposites, and AuNPs–calreticulin nanocomposite. In the untreated
control group, the wounds were moisturized with PBS. The mice in the positive control group were
treated with insulin. All wounds were inspected for 15 days, and complications were not observed
during this period. Finally, the mice were euthanized with high-dose ketamine hydrochloride.
2.16. Histological Analysis
The wound area was excised, and all tissues were fixed in 10% phosphate-buffed formaldehyde
solution for 24 h at room temperature. Then, tissues were washed with water and dehydrated through
a graded alcohol series.
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Finally, tissues were embedded in paraffin blocks, and a section of 5 µm were cut, deparaffinized,
and rehydrated. Sections were counterstained with hematoxylin and eosin (H&E) to observe the
re-epithelialization/granulation formation and Masson’s trichrome for collagen deposition.
2.17. Statistical Analysis
All the statistical analyses were performed using Graph Pad Prism 6 software, San Diego, CA,
United States All the data were expressed as mean ± standard deviation (SD). Statistical significance
was determinate using one-way ANOVA with a Tukey post-test. All the experiments were performed
in triplicate.
3. Results
3.1. Characterization of AuNPs and AuNPs–Calreticulin Nanoparticles
AuNPs and AuNPs–calreticulin nanoparticles were characterized by UV-Vis and DLS. The UV-Vis
spectra of the AuNPs had a surface plasmon resonance (SPR) peak at 524 nm, whereas for
AuNPs–calreticulin, the SPR shifted to 525 nm (Figure 1a). This 1 nm bathochromic shift is attributed to
the presence of the calreticulin on the AuNPs’ surface, which increased the diameter of the nanoparticles.
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Figure 1. UV-VIS spectra nd transmis io l tr n microscope (TEM) images. ( ) Plasmon resonance
(SPR) for g ld nanoparticles (AuNPs) an s–calreticulin obtained using chitosan as a reducing
agent; the maximun of absorbance observ 524 nm, corresponding to the formation SPR of gold
nanoparticles. (b,c) Morphology of synthesized Au Ps–calreticulin.
DLS analysis showed a increment of nanoparticle size after the functionalization. The results
showed a hydrodynamic diameter of 5.7 ± 1.07 nm, with a zeta potential of +23.9 and a polydispersity
index (PDI) of 0.3 for AuNPs, and 92.39 ± 0.94 nm with a zeta potential of +33.6 and a PDI of 0.5 for
AuNPs–calreticulin (Table 1). All measurements were obtained at 25 ◦C and a pH range of 6.5–7.5.
The TEM images showed a spherical morphology for AuNPs–calreticulin, and there was no particle
aggregation (Figure 1b,c)
Table 1. Characteristics of AuNP and AuNPs–calreticulin obtained using chitosan as reducing agent.
Measurements obtained at 25 ◦C at pH in the range of 6.5–7.5.
Nanoparticles Average Size (nm) Polydispersity Index (PDI) Z Potential (mV)
AuNPs 5.7 ± 1.07 0.3 +23.9 ± 0.002
AuNPs-calreticulin 92.39 ± 0.94 0.5 +33.6 ± 0.004
3.2. Characterization of Nanocomposites
To confirm the functionalization of AuNPs with calreticulin, the IR spectra for AuNPs and the
AuNP–calreticulin nanocomposite were recorded. Figure 2a,b showed the IR spectra for chitosan,
AuNPs, and the AuNPs–calreticulin nanocomposite in the region 4000–500 cm−1.
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Figure 2. IR spectrum of chitosan, AuNPs, and AuNPs–calreticulin. (a) Characteristic peaks of chitosan
were observed. (b) Detail of attenuated total reflection (ATR)– Fourier transform infrared spectroscopy
(FTIR) spectra between 900–1600 cm−1 shows the principal peak shifts of the interaction between
calreticulin and chitosan.
Figure 2a shows absorption peaks at 3215 cm−1, corresponding to the N–H groups of chitosan,
and thus indicating an interaction of AuNPs and AuNPs–calreticulin.
Moreover, the AuNPs and AuNPs–calr ticulin presen ed three absorption bands located at 1635,
1544, and 1336 cm−1 attributed to the amide I (C=O stretching), amide II (C–N stretching and N–H
bending vibrational modes), and an O=C–N group (vibrational modes). Table 2 shows the functional
groups of chitosan.
Table 2. Functional groups of chitosan.
Wavenumber (cm−1) Functional Group
3215 NH2
1664 C=O
1574 NH2
1336 C–N
The X-ray diffraction pattern of synthetized AuNPs and AuNPs–calreticulin is shown in Figure 3.
The diffraction peaks at 2θ values 43.2◦ (111) and 50.34◦ (200) confirming the crystalline nature of
AuNPs on the basis of the face-centered cubic (fcc) structure of gold.Nanomaterials 2019, 9, x FOR PEER REVIEW  8 of 17 
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3.3. Calreticulin Release from the Nanocomposite
The calreticulin capture efficiency in the AuNPs was 92.78% (2.8 ng), and the cumulative release
of calreticulin was characterized by a fast phase: 7.21% (0 h), 19.53% (12 h), 53.64% (24 h), and 71.52%
(48 h). After 48 h, the calreticulin was not detected (Figure 4).
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3.4. Viability Assay for Cells Treated with AuNPs–Calreticulin
Calreticulin did not affect the cell viability in HaCaT cells (Figure 5a), but in NIH/3T3 cells the
viability decreased at 72 h with concentrations of 2.5, 5, 7, and 10 pg compared with cells treated
with insulin (Figure 5b). Similarly, in the HUVEC cells we observed a decrease on the cell viability,
with a concentration of 7 pg at 24 and 72 h (Figure 5c) compared with the control.
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Figure 5. Cell viability assay. Cell treated with calreticulin (a–c), cells treated with AuNPs (d–f),
and cells treated with Au ticulin (g–i). The viability of NIH/3T3 decreased significantly with
calreticulin. Significant difference at * p < 0.05, ** p < 0.01 and *** p < 0.0001.
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On the other hand, the treatments of AuNPs and AuNPs–calreticulin did not affect the cell
viability of HaCaT, HUVEC, and NIH/3T3 cells. Also, we observed a significant increase of the cell
viability in HaCaT cells treated with AuNPs at concentrations of 3 µM (132.9%) and 6 µM (158.9%)
(Figure 5d), in NIH/3T3 cells at concentrations of 3 µM (127.1%) and 6 µM (132.2%) (Figure 5e), and in
HUVEC cells at a concentration of 3 µM (124.3%) (Figure 5f), with respect to the control.
AuNPs–calreticulin significantly increased the cell viability of HaCaT at 24 h with a concentration
of 1.5 µM (123.8%), and at 72 h with concentrations of 1.5 µM (134.5%,), 3 µM (150.4%) and 6 µM (123%)
(Figure 5g). In NIH/3T3 cells, the cell viability increased significantly at 24 h with concentrations of
1.5 µM (111.1%), 3 µM (137%), 6 µM (111.3%), and 15 µM (111%) (Figure 5h). Finally, in HUVEC cells at
72 h, a significant increase was observed with a concentration of 1.5 µM (130.9%) (Figure 5i), with respect
to the control.
3.5. Expression of Proliferating Cell Nuclear Antigen in Cells Treated with AuNPs–Calreticulin
The expression of PCNA in HaCaT, HUVEC, and NIH3/3T3 cells was determined after three
days of treatment with calreticulin, AuNPs, and AuNPs–calreticulin. The positive expression was
mainly located in the nuclear bodies and nucleoplasm. The expression in HaCaT cells treated with
calreticulin showed a significant decrease at a concentration of 7 pg (18.15 ± 1.53) (Figure 6a) with
respect to the control (27.44 ± 5.4), but in HUVEC cells (Figure 6b) and NIH/3T3 cells (Figure 6c) the
expression not was affected. On the other hand, AuNPs significantly decrease the expression of PCNA
in NIH/3T3 cells at concentrations of 3 µM (19.41 ± 0.9) and 15 µM (6.83 ± 2.5) with respect to the
control (Figure 6e), but do not affect their expression in HaCaT and HUVEC cells.
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Figure 6. Intensity of expression of proliferating cell nuclear antigen (PCNA). Cells treated with
calreticulin (a–c), AuNPs (d–f), and AuNPs–calreticulin (g–i). The expression of PCNA at day 3 was
not affected with treatments used. Significant difference at * p < 0.05, ** p < 0.01 and *** p < 0.0001.
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Finally, the expression of PCNA in cells treated with AuNPs–calreticulin was affected in NIH/3T3
cells at concentrations of 3 µM (14.06 ± 2.18) and 15 µM (6.83 ± 2.5) compared with the control
(26.89 ± 2.09) (Figure 6h). In the case of HUVEC cells, a significant difference was observed in the
expression of PCNA at a concentration of 1.5 µM (13.13± 2.59) compared with the control (19.71 ± 436)
(Figure 6i). Figure 7 corresponds to analyzed photographs for the expression of PCNA.
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Figure 7. Expression of PCNA by indirect immunofl orescent assay. (a) HaCaT cells without trea ment,
(b) 4′,6-Diamidine-2′-phenylindole dihydr chloride (DAPI), (c) cells treated with insulin, (d) DAPI,
(e) cells treated with AuNPs-calreticulin 1.5 µM, (f) DAPI, (g) human umbilical vein endothelial cells
(HUVEC) cells without treatment, (h) DAPI, (i) cells treated with insulin, (j) DAPI, (k) cells treated with
AuNPs–calreticulin 1.5 µM, (l) DAPI, (m) NIH/3T3 cells without treatment, (n) DAPI, (o) cells treated
with insulin, (p) DAPI, (q) cells treated with AuNPs-calreticulin 1.5 µM, and (r) DAPI. Expression of
PCNA (green) and DAPI (blue) pictures magnification 40×.
3.6. Colony Formation in Cells Treated with AuNPs–Calreticulin
Calreticulin does not affect colony formation in HaCaT cells (Figure 8a). In NIH/3T3 and HUVEC
cells, we observed a significant decrease in colony formation with concentrations of 5, 7, 10, and 15 pg
(Figure 8b,c) with respect control and insulin.
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Figure 8. Colony formation. Number of colonies after seven days of treatment with calreticulin (a–c),
AuNPs (d–f), and AuNPs-calreticulin (g–i). i ificant decrease was obs rved in the number of
colonies in HUVEC and NIH/3T3 cel s tre ith calreticulin, AuNPs, and AuNPs–calreticulin.
Significant difference a with respect to control and b it t insulin. Significant difference p < 0.05.
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In cells treated with AuNPs we observed a significant decrease in colony formation dependent on
the concentration of calreticulin for HaCaT, NIH/3T3, and HUVEC (Figure 8d–f).
Finally, AuNPs-calreticulin did not affect colony formation on HaCaT cells (Figure 8g); however,
we observed a decrease in the number of colonies on HUVEC and NIH/3T3 cells dependent on the
concentration. NIH/3T3 cells presented a significant increase in the number of colonies with insulin
(42.67± 1.52), compared with AuNPs–calreticulin at concentrations of 3 µM (31± 3.6), 6 µM (29± 4.58),
and 15 µM (28.67 ± 3.51) (Figure 8h). Finally, HUVEC cells presented a significant difference between
insulin (38.67 ± 5.13) and AuNPs–calreticulin at 3 µM (28 ± 2.64) and 15 µM (28 ± 3) (Figure 8i).
3.7. Wound Healing Assay of Fibroblast In Vitro
Migration results of NIH/3T3 cells treated with calreticulin (Figure 9a) and AuNPs (Figure 9b)
showed less wound closure with the treatments than with the control. However, with AuNPs–calreticulin
we observed a wound closure dependent on concentration. The concentration of 1.5 µM was the
most effective, showing wound closure of 80% at 6 h and of 100% at 12 h, in contrast with the other
treatments. Finally, at 24 h all treatments presented a closure of 100% (Figure 9c).
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Figure 9. Wound healing assay. Percentage of wound closure in mouse fibroblast cells (NIH/3T3).
(a) Cells treated with calreticulin, (b) cells treated with AuNPs and (c) cells treated with AuNPs-calreticulin.
Low concentrations of AuNPs-calreticulin showed wound closure faster than other treatments (calreticulin
and AuNPs).
3.8. Induction of Diabetes with Streptozotocin
The induction of diabetes in mice was evidenced by hyperglycemia at four weeks after the STZ
injection. Fasting blood glucose levels were increased significantly, from 100.32 ± 5.06 mg/dL in
healthy mice to 221.46 ± 7.51 mg/dL in diabetic mice.
Similarly, body weight increased significantly to 24.30± 0.66 grams in healthy mice to 25.44 ± 0.94
in diabetic mice (Table S1). A glucose tolerance test was performed to determine hyperglycemia in
diabetic mice during the evaluation period. The glucose tolerance test showed a significant increase
(p < 0.001) at 60 min in the levels of glucose in diabetic mice (515.83 ± 19.31 mg/dL) compared to
healthy mice (133.66 ± 7.47 mg/dL) (Figure S1).
3.9. Mice Treatments with Nanocomposites of AuNPs–Calreticulin
The wound heal ng in healthy mice was significan (** p < 0.001) at day 10 with the treatment of
AuNPs–calreticulin (75.30 ± 2.28%) compared with PBS (49.73 ± 3.33%) and AuNPs (54.05 ± 1.5%).
However, from day 12 to 16 we observed a significant wound closure with insulin (94.44 ± 2.06%)
compared with AuNPs (74.84 ± 1.5%) (Figure 10a), but not with AuNPs–calreticulin. Finally, a wound
closure of 100% was observed at day 18 with insulin and AuNPs–calreticulin (Figure 10a).
In diabetic mice, we observed wound healing that was significantly faster (** p < 0.001) from day
2 to 12 with AuNPs–calreticulin compared with PBS, insulin, and AuNPs (Figure 10b), and a wound
closure of 100% was observed at day 20 in wounds treated with AuNPs–calreticulin. The Figure 10c,d
indicates the area of the wounds with the different treatments on different days, which can be referred
as the scores for wound recovery.
Nanomaterials 2019, 9, 75 12 of 16
Nanomaterials 2019, 9, x FOR PEER REVIEW  13 of 17 
 
 
Figure 10. Healing of wounds of the dorsum in mice. Percent of closure of wounds in (a) healthy mice 
and (b) diabetic mice. Macroscopic view of closure wound at 0, 3, 7, and 15 days in (c) healthy mice 
and (d) diabetic mice. A reduction of the area was observed in wounds treated with AuNPs–
calreticulin in both groups. 
3.10. Histological Analysis  
The hematoxylin-eosin staining (H&E) in the healthy group and diabetic group showed 
epidermal proliferation and a normal hair growth with all treatments at day 15 (Figure 11). Also, in 
the diabetic group treated with AuNPs–calreticulin, the greatest resemblance to normal skin was 
observed, with less hypertrophic scarring and a thin epidermis in contrast with the other treatments. 
However, the growth of new blood vessels and hair follicles was very slow in this group. 
The Masson’s trichome staining after full thickness skin incision was performed and showed 
improved collagen deposition in healthy and diabetic mice treated with insulin, AuNPs, and AuNPs-
calreticulin (Figure 12). 
 
Figure 11. Hematoxylin and eosin (H&E) staining after full thickness skin incision performed. Skin 
tissue of healthy and diabetic mice at 15 days after surgery. The red arrows indicate epidermal 
Figure 10. Healing of wounds of the dorsum in mice. Percent of closure of wounds in (a) healthy mice
and (b) diabetic mice. Macroscopic view of closure wound at 0, 3, 7, and 15 days in (c) healthy mice and
(d) diabetic mice. A reduction of the area was observed in wounds treate with AuNPs–calreticulin in
both groups.
3.10. Histological Analysis
The hematoxylin-eosin taining (H&E) in the healt y group and diabetic group showed epi ermal
proliferation and a normal hair growth with all treatments at day 15 (Figure 11). Also, in the diabetic
group treated with AuNPs–calreticulin, the greatest resemblance to normal skin was observed, with less
hypertrophic scarring and a thin epidermis in contrast with the other treatments. However, the growth
of new blood vessels and hair follicles was very slow in this group.
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Figure 11. Hematoxylin and eosin (H&E) staining after full thickness skin incision performed.
Skin tissue of healthy and diabetic mice at 15 days after surgery. The red arrows indicate epidermal
proliferation, black arrows in icate hair follicle formation, and blue arrows indicate new blood vessels
(pictures magnificatio : 10×).
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The Masson’s trichome staining after full thickness skin incision was performed and showed improved
collagen deposition in healthy and diabetic mice treated with insulin, AuNPs, and AuNPs-calreticulin
(Figure 12).
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Figure 12. Masson’s trichome staining after a full thickness skin incision was performed. Skin tissue of
healthy and diabetic mice at 15 days after surgery. Collagen deposits are observed in all treatments
(black arrows), but a greater amount was observed in wounds treated with AuNPs–calreticulin (pictures
magnification: 10×).
4. Discussion
The mechanism of wound healing in diabetic foot ulcers has not been understood clearly yet,
but the search for methods and materials which can help the remodeling of wounds has been
carried out. Such is the case of metallic nanoparticles that have been used for different biological
applications [25].
In the present study, we synthetized a nanocomposite based on gold nanoparticles (AuNPs)
functionalized with calreticulin. We also evaluated the in vitro and in vivo efficacy of our nanocomposite
on the migration and proliferation of cells and remodeling of diabetic wounds. We obtained AuNPs and
AuNPs–calreticulin nanoparticles, confirmed by X-ray diffraction measurements that correspond with
the planes (200) and (111) of gold [26]. The characterization of nanoparticles based in the data of surface
plasmon resonance by UV-Vis (SPR), the distribution of size by DLS, and FTIR demonstrated a successful
functionalization with calreticulin [27]. Furthermore, the shift of bands at 1635, 1544, and 1336 cm−1
observed in AuNPs-calreticulin suggest a chemical interaction between AuNPs and calreticulin [27].
The size of the calreticulin is dependent on physiological variations of calciu ; the size range of
the calreticulin ith different concentrations of calcium was 10 to 60 nm, with an average of 20 to 17 nm
respectively and a positive charge [28]. The nanoparticles synthetized by us showed an average size of
5.2 nm (AuNPs) and 92 nm (AuNPs–calreticulin). Our results correspond with the measured range.
The release of calreticulin was constant for a period of 48 h (71.52%). This result is relevant
because calreticulin is required for fibroblast proliferation and the production of growth factors in the
first phase of the wound closure process [29].
Another finding is that the AuNPs-calreticulin nanocomposite does not significantly affect the cell
viability (80% viability) of keratinocytes and fibroblasts, suggesting that they will promote the process of
wound closure more effectively [30]. HUVEC cells were significantly affected by the AuNPs–calreticulin
at a 15µM concentration, but not by lower concentrations, suggesting that the effect of our nanocomposite
is dependent on the cell type and the concentration.
It is important to remark that our nanocomposite id not affect cell proliferation at low
concentrations, and even promoted their clonogenic capacity. These data are important because the
ability to form colonies in vitro represents one of the “gold standard” methods for the assessment of the
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clonogenic survival of cells. Also, the evaluation of colony size, type, and distribution provides additional
relevant information, especially regarding the heterogenic cell population, including mitotically active
and differentiated (mature) postmitotic cells. In this case, the size of the colony depends directly on the
proliferative capacity of cell precursors [31].
The scratch wound healing assay was used to assess cell migration, mimicking in vivo
circumstances and conditions of a wound and its repair. We found that the process of migration
is dependent on the concentration of AuNPs–calreticulin, and at lower doses the process is faster when
compared with the control. Cell migration is a key event in the wound healing process, especially
the migration of fibroblasts during the second stage of wound healing, when the granulation tissue is
formed [32].
To elucidate the biological effect of our nanocomposite in wound healing, we established a diabetic
mice model. Despite all the available diagnostic and therapeutic tools, the treatment for diabetic foot
ulcers is still deficient. The therapies should focus on increasing the necessary microvascular function,
production of growth factors, and cytokines [33].
Our in vivo results demonstrate that mice (healthy and diabetic) treated with the
AuNPs-calreticulin nanocomposite present a significantly faster closure of the wound compared
with mice treated with PBS, insulin, and AuNPs. The applicability of the nanocomposite of chitosan
and AuNPs has been demonstrated in the healing process, showing a wound closure of 100% at 19
days [34]. Correlated with this result, the histological evaluation of tissues showed re-epithelization
and the formation of granular tissue in mice treated with AuNPs–calreticulin nanocomposites, and
more deposition of collagen compared with the other treatments.
5. Conclusions
In this study, we have demonstrated satisfactory effect of AuNPs–calreticulin nanocomposite in
the cell migration of fibroblasts, proliferation of keratinocytes, and endothelial cells in vitro. In vivo
we observed the efficacy of our nanocomposite on the wound closure in a diabetic mice model,
by promoting wound healing, increasing collagen deposition, and modulation of keratinocytes and
fibroblasts, inducing a fast re-epithelization and formation of granular tissue.
In conclusion, we believe that AuNPs–calreticulin nanocomposites could be therapeutic and have
the potential to be effectively used in the treatment of diabetic foot ulcers, and should be further tested
in a clinical setting.
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